Just to put this in a separate post, ACH-1625 had a mean 3.94 log10 reduction in HCV RNA after 5 days of monotherapy in its Phase 1b. By contrast, telaprevir had a median reduction in HCV RNA of greater than 3 log10 at day 3 and a median reduction in HCV RNA of 4.4 log10 at day 14 of its Phase 1b.
Mean and median themselves can be quite different depending on the actual data so that likely further complicates a comparison. Those possible differences aside, would it be reasonable to expect ACH-1625 to go from 3.94 log10 at day 5 up to and possibly beyond 4.4 log10 at day 14 thereby surpassing the telaprevir potency data at day 14? That's a further .46 log10 reduction after nine more days. I'm sure that's impossible to say.
Market Data 
Markets 
AI
